anti-HER2 ADCs

N/A

Report date: 2025/01/26 19:00:36

Base Information

Drug Nameanti-HER2 ADCs

Drug Alias Nameanti-HER2 antibody-drug conjugate (Araris Biotech AG)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsDNA topoisomerase I inhibitors

TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I

Therapy Area/IndicationsColonic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAraris Biotech AG

China Registration ClassN/A

Develop Information

Active CompaniesAraris Biotech AG

Inactive CompaniesN/A

Active IndicationsColonic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A